com puted tomography (CT) scan prem edicat ion). Dose- expansion phase Deviat ion 1: Pati ents who received a dose of study treatm ent other than the dose that was intended 1.1Patient ei ther did not receive any dose of planned study treatment or di d not receive the correct dose of planned study treatm ent (i .e. less than 75% of the planned dose at the time of infusion) (as per Fig ure 1 in the CSP). Deviat ion 2: Pati ents who deviate from key entry criteria as per the CSP. These are inclusio n criteria 2, 3, 6 and 8 and exclusio n criteria 11: 2.1 Patient, ol der than 18 y ears, received study treatm ent (inclusio n criteria 2). 2.2 Patient received study treatment without a histopatho logic confirmat ion of a malignancy or/and have not progressed or were refractory to standard therapies or/and have not explored standard of care treatments before participat ion on this protocol . (inclusio n criteria 3). 2.3 Selection of a previously radiated tumor as a target lesio n and tum or did not show di sease progressi on pri or to study entry (inclusion criteria 6). 2.4 Inadequate organ and marrow function, defined as any of the fo llowing (inclusio n criteria 8): -Hem oglobin < 9.0 g/dL -Absolute neutrophil count < 1.0 × 109/L -Platelet coun t < 75 × 109/L -Serum bilirubin > 1.5 × the ULN Statistical Analysis Plan Study Code D419EC00001 Edition Number 4.0 Date 19Apr2023 CONFIDENTIAL AND PROPRIETARY 26of 65-Creatinine clearance ≤ 60 mL/min - Alanine transaminase (ALT) or aspartate transaminase (AST) > 3 × upper limit of normal (ULN) (for patien ts wi thout liver metastases) -ALT or AST > 5 × ULN (for patients with liver metastases) 2.5 Received the last dose of an ant icancer therapy (chem otherapy , immunotherapy , endocrine therapy , targeted therapy , biologic therapy , tum or embo lization, or mAbs) ≤28 days or l ess than 5 half -lives of the drug, whichever is shorter (and minimum o f 7 day s), pri or to the first dose of study treatm ent (exclusio n criteria 11). 2.6 Received any anti-cancer therapy (chemotherapy , immunotherapy , endocrine therapy , targeted therap y, biologic therapy , tum or embo lization, or mAbs) between Cycle 1, Day 1 and Cycle 3, Day 1(exclusi on criteria 11).